학술논문
Early Multicenter Experience With Imipenem-Cilastatin-Releb actam for Multidrug-Resistant Gram-Negative Infections
BRIEF REPORT
BRIEF REPORT
Document Type
Academic Journal
Author
Source
Open Forum Infectious Diseases. December 2021, Vol. 8 Issue 12
Subject
Language
English
ISSN
2328-8957
Abstract
The increasing prevalence and spread of resistant gram-negative bacteria, such as multidrug-resistant (MDR) Pseudomonas aeruginosa and carbapenem-resistant Enterobacterales (CRE), are of high concern [1, 2]. Encouragingly, agents displaying in vitro [...]
A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects. Keywords. carbapenem-resistant Enterobacterales; imipenemcilastatin-relebactam; multidrug-resistant; Pseudomonas aeruginosa.
A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects. Keywords. carbapenem-resistant Enterobacterales; imipenemcilastatin-relebactam; multidrug-resistant; Pseudomonas aeruginosa.